Fulgent Genetics Stock Forecast, Price & News

Fulgent Genetics' stock was trading at $10.06 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, FLGT shares have increased by 603.0% and is now trading at $70.72.
View which stocks have been most impacted by COVID-19.

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fulgent Genetics in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Fulgent Genetics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FLGT, but not buy additional shares or sell existing shares.
View analyst ratings for Fulgent Genetics or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Fulgent Genetics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Fulgent Genetics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Fulgent Genetics is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for Fulgent Genetics.

Fulgent Genetics, Inc. (NASDAQ:FLGT) issued its quarterly earnings results on Monday, November, 9th. The company reported $2.08 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.39 by $1.69. The business earned $101.72 million during the quarter, compared to the consensus estimate of $51.73 million. Fulgent Genetics had a net margin of 35.31% and a return on equity of 43.81%.
View Fulgent Genetics' earnings history.

Fulgent Genetics updated its FY 2020 Pre-Market earnings guidance on Monday, November, 23rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $300 million, compared to the consensus revenue estimate of $237.38 million.

5 equities research analysts have issued 12 month price objectives for Fulgent Genetics' shares. Their forecasts range from $20.00 to $100.00. On average, they expect Fulgent Genetics' stock price to reach $55.40 in the next twelve months. This suggests that the stock has a possible downside of 21.7%.
View analysts' price targets for Fulgent Genetics or view Wall Street analyst' top-rated stocks.

Some companies that are related to Fulgent Genetics include Elekta AB (publ) (EKTAY), CareDx (CDNA), Burning Rock Biotech (BNR), Veracyte (VCYT), Genetron (GTH), Personalis (PSNL), Castle Biosciences (CSTL), RadNet (RDNT), Renalytix AI (RNLX), DermTech (DMTK), Progenity (PROG), Centogene (CNTG), Exagen (XGN), Enzo Biochem (ENZ) and Celcuity (CELC).
View all of FLGT's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Fulgent Genetics investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), NeoGenomics (NEO), Invitae (NVTA), Square (SQ), JD.com (JD), Marvell Technology Group (MRVL), Teladoc Health (TDOC) and Editas Medicine (EDIT).

(FLGT) raised $60 million in an initial public offering (IPO) on Thursday, September 29th 2016. The company issued 4,600,000 shares at $12.00-$14.00 per share. Credit Suisse and Piper Jaffray served as the underwriters for the IPO and Raymond James and BTIG were co-managers.

Fulgent Genetics trades on the NASDAQ under the ticker symbol "FLGT."

Fulgent Genetics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Raymond James Trust N.A. (1.39%), Crossmark Global Holdings Inc. (0.06%), New England Research & Management Inc. (0.06%), State of Alaska Department of Revenue (0.04%) and Louisiana State Employees Retirement System (0.02%). Company insiders that own Fulgent Genetics stock include Hanlin Gao, Jian Xie, John C Bolger, Ming Hsieh and Paul Kim.
View institutional ownership trends for Fulgent Genetics.

FLGT stock was sold by a variety of institutional investors in the last quarter, including Raymond James Trust N.A.. Company insiders that have sold Fulgent Genetics company stock in the last year include Hanlin Gao, Jian Xie, John C Bolger, and Paul Kim.
View insider buying and selling activity for Fulgent Genetics or view top insider-selling stocks.

FLGT stock was purchased by a variety of institutional investors in the last quarter, including Crossmark Global Holdings Inc., New England Research & Management Inc., Louisiana State Employees Retirement System, and State of Alaska Department of Revenue.
View insider buying and selling activity for Fulgent Genetics or or view top insider-buying stocks.

Shares of FLGT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of FLGT stock can currently be purchased for approximately $70.72.

Fulgent Genetics has a market capitalization of $1.72 billion and generates $32.53 million in revenue each year. The company earns $-410,000.00 in net income (profit) each year or $0.02 on an earnings per share basis. Fulgent Genetics employs 473 workers across the globe.

The official website for Fulgent Genetics is www.fulgentgenetics.com.

Fulgent Genetics' mailing address is 4978 SANTA ANITA AVENUE, TEMPLE CITY CA, 91780. The company can be reached via phone at 626-350-0537 or via email at [email protected]